Low-dose Y90 Treatment Planning for HCC

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 16, 2019

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
HCCCancer of LiverCancer
Interventions
DEVICE

SIR-Spheres microspheres

SIR-Spheres® Y-90 resin microspheres consist of biocompatible polymer resin microspheres of a median diameter of 32.5 microns (range between 20 and 60 microns) loaded with yttrium-90 (beta radiation penetrating an average of 2.5 mm in tissue to destroy tumor cells). The resin microspheres are small enough to become lodged in the arterioles within the growing rim of the tumor but are too large to pass through the capillaries and into the venous system. Since yttrium-90 has a half-life of 64.1 hours, most of the radiation (94%) is delivered to the tumor over 11 days.

Trial Locations (3)

30308

Emory University Midtown, Atlanta

30322

Emory Clinic, Atlanta

Emory University Hospital, Atlanta

All Listed Sponsors
lead

Emory University

OTHER

NCT04172714 - Low-dose Y90 Treatment Planning for HCC | Biotech Hunter | Biotech Hunter